Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers
AssigneeJulius-Maximilians-UniversitäT WüRzburg
InventorsJörg Wischhusen, Markus Haake, Reinhard Dummer, Matthias Mehling, Tina Schäfer, Martina Selle
Life of this patent
Estimating the term…
Abstract
The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.
Claims18
A method of increasing the percentage of CD8+ T-cells in a GDF-15-expressing solid cancer in a patient in need thereof, the method comprising administering to the patient a combination of an antibody that specifically binds to human GDF-15 (hGDF-15), or an antigen-binding portion thereof, and an immune checkpoint blocker selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, and combinations thereof.
A method of treating a GDF-15-expressing solid cancer in a patient in need thereof, the method comprising administering to the patient a combination of an antibody that specifically binds to hGDF-15, or an antigen-binding portion thereof, and an immune checkpoint blocker selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, and combinations thereof.
Dependencies are inferred from the claim text.